Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Deviation / Variation In Utilization Of Funds Raised Through IPO
Statement of Deviation / Variation in Utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2024.
Tatva Chintan Pharma Chem Ltd. Results Earnings Call for Q4FY24
Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and financial year ended 31 March 2024. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Dividend Updates
Outcome of Board Meeting - Board approves Dividend Tatva Chintan Pharma Chem Ltd - 543321 - Corporate Action-Board approves Dividend
Outcome of Board Meeting - Board approves Dividend Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 03.05.2024
Outcome Of The Board Meeting Held On 03.05.2024 Tatva Chintan Pharma Chem Ltd - 543321 - Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended On 31 March 2024
Audited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Financial Year Ended On 31 March 2024. Tatva Chintan Pharma Chem Ltd - 543321 - Intimation Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Environmental Clearance
Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Environmental Clearance Tatva Chintan Pharma Chem Ltd - 543321 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Tatva Chintan Pharma Chem Ltd 2 CIN NO. L24232GJ1996PLC029894 3 Report filed for FY 2023-2024 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2023-24 and FY 2024-25 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2022-23 and FY 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Ishwar NayiDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Ashok Bothra Designation : -Chief Financial Officer Date:... Tatva Chintan Pharma Chem Ltd - 543321 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyTatva Chintan Pharma Chem Ltd 2CIN NO.L24232GJ1996PLC029894 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 4.27 4Highest Credit Rating during the previous FY A- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ishwar Nayi Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Ashok Bothra Designation: Chief Financial Officer EmailId: [email protected] Date: 29/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.